Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
- Astellas’ Pompe Gene Therapy Proves Safe in PI/II Interim Data
February 9, 2022
- Japan Ethical Drug Sales Up 3.9% in December: Crecon
February 9, 2022
- Sales Reps’ Detailing Activities Decrease MOM, YOY in December: Intage
February 9, 2022
- New Disease Target Picked in Sosei-Takeda Drug Discovery Pact
February 9, 2022
- Sumitomo Dainippon to Boost Infectious Disease R&D, Eyes AMR/Malaria
February 8, 2022
- Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
- Kyowa Kirin Nets 50%-Plus Sales from Overseas in 2021, Crysvita as Major Driver
February 8, 2022
- Cosentyx 75 mg Syringe Now Available in Japan: Novartis
February 8, 2022
- Kyoto Univ. Spinoff, CiRA, AZ to Develop Method to Produce iPSC-Derived Renal Tissues
February 8, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Meiji Unit Slapped with £4.62 Million Fine over Anti-Competitive Practices in UK
February 8, 2022
- Kyorin Holdings to Merge Pharma Subsidiary in April 2023
February 7, 2022
- Opdivo Tops Japan Sales Ranking in January: Encise
February 7, 2022
- Aculys Pharma Begins Japan PI for Narcolepsy Drug Candidate
February 7, 2022
- Fujifilm to Boot Up Corporate Venture Capital for Life Science
February 7, 2022
- Mochida Files Inhaled Treprostinil for PAH in Japan
February 7, 2022
- Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
- Eisai Aims for US Accelerated OK for Lecanemab in 2022; Japan/EU Filing Planned by March 2023
February 4, 2022
- Mitsubishi Tanabe’s 9 Month Sales Rise Fueled by Strong Growth in Stelara
February 4, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…